• Tourmaline Bio Inc TRML.OQ reported a quarterly adjusted loss of 90 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -68 cents. The mean expectation of ten analysts for the quarter was for a loss of 94 cents per share. Wall Street expected results to range from $-1.05 to -78 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Tourmaline Bio Inc's reported EPS for the quarter was a loss of 90 cents​.

• The company reported a quarterly loss of $23.09 million.

• Tourmaline Bio Inc shares had risen by 34.3% this quarter and gained 5.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Tourmaline Bio Inc is $56.50, about 62% above its last closing price of $21.48

This summary was machine generated from LSEG data August 13 at 11:33 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)